The Role of Rho Kinase Inhibitors in Corneal Diseases
Stefan Futterknecht,Eleftherios Chatzimichail,Konstantin Gugleta,Georgios Panos,Zisis Gatzioufas
DOI: https://doi.org/10.2147/dddt.s435522
IF: 4.3188
2024-01-20
Drug Design Development and Therapy
Abstract:Stefan Futterknecht, 1, 2 Eleftherios Chatzimichail, 1 Konstantin Gugleta, 1, 3 Georgios D Panos, 4, 5, &ast Zisis Gatzioufas 1, 3, &ast 1 Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland; 2 Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland; 3 Department of Ophthalmology, School of Medicine, University of Basel, Basel, Switzerland; 4 Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK; 5 Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, UK &astThese authors contributed equally to this work Correspondence: Georgios D Panos, Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals, Derby Road, Lenton, Nottingham, NG7 2UH, UK, Tel +44 115 924 9924, Email The cornea, as the outermost layer of the eye, plays a crucial role in vision by focusing light onto the retina. Various diseases and injuries can compromise its clarity, leading to impaired vision. This review aims to provide a thorough overview of the pharmacological properties, therapeutic potential and associated risks of Rho-associated protein kinase (ROCK) inhibitors in the management of corneal diseases. The article focuses on four key ROCK inhibitors: Y-27632, fasudil, ripasudil, and netarsudil, providing a comparative examination. Studies supporting the use of ROCK inhibitors highlight their efficacy across diverse corneal conditions. In Fuchs' endothelial corneal dystrophy, studies on the application of Y-27632, ripasudil, and netarsudil demonstrated noteworthy enhancements in corneal clarity, endothelial cell density, and visual acuity. In pseudophakic bullous keratopathy, the injection of Y-27632 together with cultured corneal endothelial cells into the anterior chamber lead to enhanced corneal endothelial cell density and improved visual acuity. Animal models simulating chemical injury to the cornea showed a reduction of neovascularization and epithelial defects after application of fasudil and in a case of iridocorneal endothelial syndrome netarsudil improved corneal edema. Addressing safety considerations, netarsudil and ripasudil, both clinically approved, exhibit adverse events such as conjunctival hyperemia, conjunctival hemorrhage, cornea verticillata, conjunctivitis, and blepharitis. Monitoring patients during treatment becomes crucial to balancing the potential therapeutic benefits with these associated risks. In conclusion, ROCK inhibitors, particularly netarsudil and ripasudil, offer promise in managing corneal diseases. The comparative analysis of their pharmacological properties and studies supporting their efficacy underscore their potential therapeutic significance. However, ongoing research is paramount to comprehensively understand their safety profiles and long-term outcomes in diverse corneal conditions, guiding their optimal application in clinical practice. Keywords: rho kinase inhibitors, cornea, corneal diseases, corneal dystrophies, Fuchs' endothelial corneal dystrophy, corneal transplantation The cornea, the transparent outermost layer of the eye, plays a crucial role in refracting and focusing light onto the retina, making clear vision possible. Various diseases, injuries, and surgical procedures can compromise the integrity and function of the cornea, leading to vision impairment and blindness. 1,2 The cornea is composed of five layers, including the epithelium, Bowman's layer, stroma, Descemet's membrane, and endothelium. The corneal endothelium is a single layer of cells that lines the posterior surface of the cornea and is essential for maintaining the corneal transparency by regulating the flow of fluids into and out of the cornea. Dysfunction of the corneal endothelium, as seen in Fuchs' endothelial corneal dystrophy (FECD), can lead to corneal edema, opacification, and ultimately, vision loss. 3,4 As corneal endothelial cells have very limited capacity to regenerate, current therapies for corneal endothelial diseases focus on managing the symptoms rather than restoring the function of the damaged endothelium. The mainstay of treatment is corneal transplantation. However, these procedures are associated with several limitations, such as the shortage of donor corneas and the risk of graft rejection. Rho-associated protein kinase (ROCK) is a serine/threonine kinase that regulates various cellular processes. 5–7 Dysregulation of ROCK signaling has been implicated in various pathological conditions, such as cancer, cardiovascular diseases, and neurological disorders. 8,9 ROCK inhibitors refer to a class of pharm -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal